Assessment of Cell Proliferation in Renal Cell Carcinoma Using Dual-phase F-fluorodeoxyglucose PET/CT

Overview

Journal Oncol Lett

Specialty Oncology

Date 2015 Dec 2

PMID 26622577

Citations 6

Authors

Rei Onishi

Masanori Noguchi

Hayato Kaida

Fukuko Moriya

Katsuaki Chikui

Seiji Kurata

Akihiko Kawahara

Masayoshi Kage

Masatoshi Ishibashi

Kei Matsuoka

Affiliations

Soon will be listed here.

Abstract

The present study aimed to examine the association between F-fluorodeoxyglucose (F-FDG) uptake and cell proliferation markers; in addition, the correlation between F-FDG uptake and biological characteristic in patients with renal cell carcinoma (RCC) was investigated using dual-phase F-FDG-positron emission tomography/computed tomography (PET/CT). Dual-phase F-FDG PET/CT was performed on 31 RCC patients and the maximum standardized uptake values at 1 h (SUV1) and 2 h (SUV2) as well as the retention index (RI; %) in the primary tumors were calculated. Monoclonal antibodies for Ki-67, minichromosome maintenance 2 (MCM2) and topoisomerase II α (topo II α) were used to assess the expression levels of their respective proteins in excised tumor tissue using immunohistochemistry. The results demonstrated that RI and SUV2 in patients with Stage I/II + grade 1 (G1) RCC were significantly decreased compared with all patients with other stages/grades (RI, P=0.0065; SUV2, P=0.043); in addition, significantly increased uptake and RI were detected in patients with metastases compared with patients without metastases (SUV1, P=0.029; SUV2, P=0.0003; RI, P<0.001). All proliferation markers significantly correlated with RI (Ki-67, r=0.501, P=0.004; MCM2, r=0.359, P=0.047; topo II α, r=0.402, P=0.024), while SUV1 and SUV2 correlated with Ki-67 only. In conclusion, the results of the present study demonstrated that dual-phase F-FDG-PET/CT was more useful for predicting cell proliferation in RCC compared with single-phase imaging alone. However, follow-ups are required in order to determine whether dual-phase F-FDG-PET/CT provides independent prognostic information.

Citing Articles

FDG-PET Positivity and Overall Survival in Renal Cell Carcinoma.

Ferdinandus J, Maric I, Darr C, Kesch C, Bartel T, Fendler W JAMA Netw Open. 2022; 5(11):e2242289.

PMID: 36383385 PMC: 9669811. DOI: 10.1001/jamanetworkopen.2022.42289.

Giant Polycystic Papillary Renal Cell Carcinoma: A Case Report and Literature Review.

Huang Z, Wang H, Ji Z Front Oncol. 2022; 12:876217.

PMID: 35646650 PMC: 9134105. DOI: 10.3389/fonc.2022.876217.

A prospective study on dual time F-FDG-PET/CT in high-risk prostate cancer patients.

Mortensen M, Vilstrup M, Poulsen M, Gerke O, Hoilund-Carlsen P, Lund L BMC Res Notes. 2018; 11(1):871.

PMID: 30526642 PMC: 6286604. DOI: 10.1186/s13104-018-3985-2.

F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value.

Liu S, Feng Z, Wen H, Jiang Z, Pan H, Deng Y Jpn J Radiol. 2018; 36(9):544-550.

PMID: 29943313 DOI: 10.1007/s11604-018-0755-y.

PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art.

Razik A, Das C, Sharma S Indian J Urol. 2018; 34(1):20-27.

PMID: 29343908 PMC: 5769244. DOI: 10.4103/iju.IJU_321_17.

References

Folpe A, Lyles R, Sprouse J, Conrad 3rd E, Eary J . (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000; 6(4):1279-87. View

Mitsudomi T, Hamajima N, Ogawa M, Takahashi T . Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res. 2000; 6(10):4055-63. View

Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede M, Wada M . Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002; 43(2):173-80. View

Rodins K, Cheale M, Coleman N, Fox S . Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility. Clin Cancer Res. 2002; 8(4):1075-81. View

Aide N, Cappele O, Bottet P, Bensadoun H, Regeasse A, Comoz F . Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging. 2003; 30(9):1236-45. DOI: 10.1007/s00259-003-1211-4. View

Zhao S, Kuge Y, Mochizuki T, Takahashi T, Nakada K, Sato M . Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med. 2005; 46(4):675-82. View

Dudderidge T, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths D . Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res. 2005; 11(7):2510-7. DOI: 10.1158/1078-0432.CCR-04-1776. View

Dekel Y, Frede T, Kugel V, Neumann G, Rassweiler J, Koren R . Human DNA topoisomerase II-alpha expression in laparoscopically treated renal cell carcinoma. Oncol Rep. 2005; 14(1):271-4. View

Kankuri M, Soderstrom K, Pelliniemi T, Vahlberg T, Pyrhonen S, Salminen E . The association of immunoreactive p53 and Ki-67 with T-stage, grade, occurrence of metastases and survival in renal cell carcinoma. Anticancer Res. 2006; 26(5B):3825-33. View

10.

Nguyen X, Lee W, Chung J, Park S, Sung S, Kim Y . FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol. 2007; 62(2):214-9. DOI: 10.1016/j.ejrad.2006.12.008. View

11.

Noguchi M, Yao A, Harada M, Nakashima O, Komohara Y, Yamada S . Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate. 2007; 67(9):933-42. DOI: 10.1002/pros.20572. View

12.

Wahl R, Harney J, Hutchins G, Grossman H . Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies. J Urol. 1991; 146(6):1470-4. DOI: 10.1016/s0022-5347(17)38141-7. View

13.

Dooms C, van Baardwijk A, Verbeken E, van Suylen R, Stroobants S, De Ruysscher D . Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer. J Thorac Oncol. 2009; 4(7):822-8. DOI: 10.1097/JTO.0b013e3181a97df7. View

14.

Albadine R, Wang W, Brownlee N, Toubaji A, Billis A, Argani P . Topoisomerase II alpha status in renal medullary carcinoma: immuno-expression and gene copy alterations of a potential target of therapy. J Urol. 2009; 182(2):735-40. PMC: 3505671. DOI: 10.1016/j.juro.2009.03.078. View

15.

Groheux D, Martineau A, Vrigneaud J, Hindie E, Baillet G, Moretti J . Effect of variation in relaxation parameter value on LOR-RAMLA reconstruction of 18F-FDG PET studies. Nucl Med Commun. 2009; 30(12):926-33. DOI: 10.1097/MNM.0b013e32832ed3cf. View

16.

Gianni L, Norton L, Wolmark N, Suter T, Bonadonna G, Hortobagyi G . Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol. 2009; 27(28):4798-808. DOI: 10.1200/JCO.2008.21.4791. View

17.

Murakami S, Saito H, Sakuma Y, Mizutani Y, Ishikawa Y, Kondou T . Correlation of 18F-fluorodeoxyglucose uptake on positron emission tomography with Ki-67 index and pathological invasive area in lung adenocarcinomas 30 mm or less in size. Eur J Radiol. 2009; 75(2):e62-6. DOI: 10.1016/j.ejrad.2009.11.020. View

18.

Lawrentschuk N, Davis I, Bolton D, Scott A . Functional imaging of renal cell carcinoma. Nat Rev Urol. 2010; 7(5):258-66. DOI: 10.1038/nrurol.2010.40. View

19.

Kumar R, Shandal V, Shamim S, Jeph S, Singh H, Malhotra A . Role of FDG PET-CT in recurrent renal cell carcinoma. Nucl Med Commun. 2010; 31(10):844-50. DOI: 10.1097/MNM.0b013e32833d6882. View

20.

Namura K, Minamimoto R, Yao M, Makiyama K, Murakami T, Sano F . Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer. 2010; 10:667. PMC: 3016292. DOI: 10.1186/1471-2407-10-667. View